Pursuant to the provisions of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Listing Regulations’) (as amended), Jubilant Pharmova has informed that the Board of Directors of the Company has, at its meeting held today on Friday, July 19, 2024 at 12:15 pm that concluded at 02:00 pm, approved the following: Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024; Grant of 45,448 Stock Options to the eligible employees under the Jubilant Pharmova Employees Stock Option Plan 2018. Pursuant to applicable provisions of the Listing Regulations, it has enclosed the following: The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024; Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; The details pursuant to SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Circular dated July 13, 2023 with respect to Stock Options granted to the eligible employees is annexed as Annexure -1. The above-mentioned documents will be simultaneously posted on the Company's website at www.jubilantpharmova.com.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1830.20 |
Dr. Reddys Lab | 1183.00 |
Cipla | 1549.65 |
Lupin | 2094.65 |
Zydus Lifesciences | 887.70 |
View more.. |